Skip to main content

Year: 2024

embecta Celebrates National Diabetes Awareness Month by Ringing Nasdaq Closing Bell

Advocacy and professional groups join global diabetes care company at Nasdaq to raise awareness of diabetes, while also commemorating the company’s 100-year legacy of serving this community PARSIPPANY, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) — Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, announced it will ring the Nasdaq Closing Bell today in recognition of National Diabetes Awareness Month in November, celebrating the strength, well-being, and individuality of people living with diabetes. Advocacy and professional groups including the Association of Diabetes Care & Education Specialists (ADCES), Beyond Type 1, Beyond Type 2, Camp Nejeda, Children with Diabetes, Diabetes Education and Camping Association (DECA), the Diabetes Foundation, Taking Control of Your Diabetes (TCOYD), The Diabetes Link, and...

Continue reading

Taboola Reports Strong Q3 2024, Beating Revenues, ex-TAC and Adj. EBITDA; Reiterating 2024 Revenues, ex-TAC, & Adj. EBITDA Guidance; Raising 2024 Free Cash Flow Target

Q3 2024 and FY 2024 Key HighlightsQ3 Financials – Beat on Revenues, ex-TAC, and Adj. EBITDA; $97M YTD FCF already approaching FY 2024 target of $100M+Q3 2024 Results: Revenues $433M, Gross profit $133M, ex-TAC Gross Profit $166M, Net loss $6M, Non-GAAP Net Income $22M, Adj. EBITDA $48M, Free Cash Flow $43M Strong YoY growth: Revenues +20%, ex-TAC +30%, Adj. EBITDA +110%, FCF +88% Strong Free Cash Flow conversion: 89% conversion from Adj. EBITDAReiterating 2024 Revenues, ex-TAC, Adj. EBITDA guidance; Growth rates accelerate across all metrics; Raising 2024 FCF Target to $105M+Q4 guidance: $475M in Revenues (+13% YoY), $188M Gross profit (+36% YoY), $213M ex-TAC Gross Profit (+26% YoY), $91M Adj. EBITDA (+82% YoY)* Reiterating 2024 guidance: $1,750M Revenues (+22% YoY), $667M ex-TAC Gross Profit (+25% YoY), $200M+...

Continue reading

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations Into at Least 2026 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the third quarter ended September 30, 2024,...

Continue reading

Verano Announces Third Quarter 2024 Financial Results

CHICAGO, Nov. 07, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the third quarter ended September 30, 2024, which were prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). Third Quarter 2024 Financial Highlights    For the Three Months Ended,  ($ in thousands)   September 30, 2024     June 30, 2024     September 30, 2023  Revenues, net of Discounts   $ 216,683     $ 222,390     $ 240,088  Gross Profit     109,097       114,340       133,220  Income from Operations     16,770       27,266       40,288  Net Loss Attributable to Verano Holdings Corp. & Subsidiaries     (42,567 )     (21,764 )     (17,842 )Adjusted EBITDA1     64,458       70,599       89,349  Third...

Continue reading

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and New to Brand Prescriptions Grew 18% from Second Quarter – – October 2024 Total Retail Prescription Equivalents Increased 17% and New to Brand Prescriptions Grew 20% Compared to First Four Weeks of Q3 2024 – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Nov. 07, 2024 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “The year to date has been transformational for Esperion. We successfully expanded our product labels, scaled up our commercial team and launched new indications, which have driven double-digit prescription...

Continue reading

Millicom (Tigo) Q3 2024 Earnings Release

Millicom (Tigo) Q3 2024 Earnings Release Luxembourg, November 7, 2024 – Millicom is pleased to announce its third quarter 2024 results. Please find below links to the Q3 2024 Earnings Release and IAS 34 Interim Condensed Consolidated Financial Statements. Highlights*Revenue $1.43 billion up 0.5% – Service Revenue up 1.8% (2.4% organically)   Robust commercial activity: 299,000 Postpaid Mobile and 68,000 Home FTTH/HFC net additions Operating profit $300 million, up 43.1% EBITDA $585 million, up 9.8% Net income $51 million ($0.30 per share) Equity free cash flow $271 million, up from $100 million in Q3 2023 Leverage 2.59x, down 0.18x from 2.77x at Q2Financial highlights ($ millions) Q3 2024 Q3 2023 Change % Organic % Change 9M 2024 9M 2023 Change % Organic % Change...

Continue reading

Dentsply Sirona Reports Third Quarter 2024 Results

Net sales of $951 million increased 0.5%, organic sales increased 1.3% GAAP gross margin of 52.1%, GAAP net loss of ($494) million or loss per share of ($2.46) Adjusted EBITDA margin of 17.9%, adjusted EPS of $0.50 Revised FY24 outlook: expect organic sales of (3.5%) to (2.5%) (previously (1%) to flat); adjusted EPS of $1.82 to $1.86 (previously $1.96 to $2.02)CHARLOTTE, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced its financial results for the third quarter of 2024. Third quarter net sales of $951 million increased 0.5% (organic sales increased 1.3%) compared to the third quarter of 2023. Foreign currency changes negatively impacted third quarter 2024 net sales by ($8) million. Net loss was ($494) million, or ($2.46) per share, compared...

Continue reading

MT Højgaard Holding A/S: Conference call 14 November at 10.00 CET about Q3 2024

MT Højgaard Holding releases its interim report for Q3 2024 on 14 November 2024 and hosts a conference call at 10.00 (CET) that date at which the management will present the results and outlook before answering questions. Registration is not required. The conference call will be conducted in Danish and can be heard live here or at www.mthh.dk, where the accompanying presentation will be available. Participants should dial the numbers provided below and enter PIN 531691.Denmark +45 78768490UK +44 203-7696819US +1 646-787-0157Additional information:Phone +45 31 21 68 72.AttachmentMTHH_Investor news (conference call)

Continue reading

Townsquare Returns to Total and Digital Revenue Growth in the Third Quarter

Digital Represents 52% of September YTD Total Net RevenueIgnite’s Digital Advertising Revenue Growth Accelerates in Q3Repurchased $25 Million of Debt ($36M through October) and $24 Million of Equity in September YTD Period PURCHASE, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) — Townsquare Media, Inc. (NYSE: TSQ) (“Townsquare”, the “Company,” “we,” “us,” or “our”) announced today its financial results for the third quarter ended September 30, 2024. “I am pleased to share that Townsquare’s net revenue returned to year-over-year growth, driven by sequential improvement across each of our three business segments, due to our local focus and our unique and differentiated digital platform, as well as the benefit from political revenue. Third quarter net revenue increased +0.2% year-over-year...

Continue reading

Barrick Mines Set to Deliver Strong Finish to the Year

Third Quarter 2024 ResultsAll amounts expressed in U.S. dollars TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) dealt with ongoing challenges and made significant progress on many fronts in the third quarter of the year to keep its annual production and cost guidance within reach on the back of the strong performance anticipated in Q4. Gold production was in line with that of the previous quarter while copper production was up 12% quarter on quarter. The Company said it was on track for a materially improved Q4, driven by the continuing ramp-up of the Pueblo Viejo plant expansion, increased throughput at Nevada Gold Mines and higher grades at Kibali. Improved margins across the gold operations reflected the higher gold price and cost discipline. Net earnings per share rose by 33% year on...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.